a hrefhttps:www.fiercepharma.compharmajazz-withdraw-zepzelca-fda-second-line-small-cell-lung-cancer hreflangenJazz to withdraw Zepzelca with FDA in second-line small cell lung cancera

After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer.